Immutep Ltd
IMMPImmutep Ltd in brief
Immutep Ltd is a listed company in the Biotechnology industry, based in Australia. It was founded in 2001. Its market value was $56 M on 1 August 2026, which makes it the 20,866th largest listed company in the world and the 506th largest in Australia on this site. In the year to June 2025 it had sales of $7 M and a net loss of $40 M. Its shares trade under the symbol IMMP (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Immutep Ltd
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Immutep Ltd timeline
- 1988
- 📈Listed on Australian Securities Exchange as IMM
- 2001
- 🏁· approximateFounded
- 2012
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed IMMUTEP LtdFormerly Prima BioMed Ltd.
Events of Immutep Ltd from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #442 (Jan 2020) · #339 (Jan 2021) · #418 (Jan 2022) · #412 (Dec 2022) · #388 (Jul 2023) · #93 (Jan 2024) · #2 (Mar 2026) · #506 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 8.4×
- Price / book
- 0.6×
- Free cash flow yield
- -71.8%
- Net margin (TTM)
- -594.8%
- Operating margin
- —
- Return on equity
- -42.4%
- Liabilities / assets
- 8.5%
- Revenue growth
- +30.2%
- R&D / revenue
- 481.9%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | $7M | +30.2% | — | $-40M | -594.8% |
| Jun 2024 | $5M | +46.9% | — | $-28M | -544.6% |
| Jun 2023 | $4M | -28.6% | — | $-27M | -766.9% |
| Jun 2022 | $5M | +65.5% | — | $-23M | -476.7% |
| Jun 2021 | $3M | -73.2% | — | $-22M | -753.4% |
| Jun 2020 | $11M | +106.3% | — | $-9M | -81.6% |
| Jun 2019 | $5M | -6.0% | — | $-13M | -244.8% |
| Jun 2018 | $6M | — | — | $-10M | -173.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2025 | $-40M | $0M | $-40M | $-0.03 | — |
| Jun 2024 | $-23M | $0M | $-23M | $-0.02 | — |
| Jun 2023 | $-24M | $0M | $-24M | $-0.03 | — |
| Jun 2022 | $-22M | $0M | $-22M | $-0.03 | — |
| Jun 2021 | $-13M | $0M | $-13M | $-0.04 | — |
| Jun 2020 | $-7M | $0M | $-7M | $-0.02 | — |
| Jun 2019 | $-11M | $0M | $-11M | $-3.78 | — |
| Jun 2018 | $-6M | $0M | $-6M | $-3.59 | — |
SEC filings
- Nov 10, 20266-KReport of foreign issuer
- Nov 2, 20266-KReport of foreign issuer
- Oct 29, 20266-KReport of foreign issuer
- Oct 23, 202620-FAnnual report (foreign issuer) · period to Jun 2026
- Oct 14, 20266-KReport of foreign issuer
- Sep 22, 20266-KReport of foreign issuer
- Sep 11, 20266-KReport of foreign issuer
- Sep 2, 20266-KReport of foreign issuer
- Aug 3, 20266-KReport of foreign issuer
- Jul 14, 20266-KReport of foreign issuer
- Jun 5, 20266-KReport of foreign issuer
- May 1, 20266-KReport of foreign issuer
Official filings of Immutep Ltd with the US Securities and Exchange Commission.
Annual results
- Revenue
- $7 M
- Operating income
- —
- Net income
- $-40 M
For year ending June-2025 · source: SEC filing
Balance sheet
- Total assets
- $103 M
- Total liabilities
- $9 M
- Total equity
- $94 M
As of June-2025
Immutep Ltd products and services
Search all products and services →Products (1)
Experimental drug
- etilagimod alpha
Experimental cancer drug
Top 10 institutional investors in Immutep Ltd#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 40,456 | New | $0 M | Nov 13, 2026 |
| 2 | HSBC Holdings PLC | 27,755 | New | $0 M | Nov 16, 2026 |
| 3 | Rhumbline Advisers | 1,888 | New | $0 M | Nov 10, 2026 |
| 4 | UBS Group AG | 561 | New | $0 M | Nov 10, 2026 |
| 5 | US Bancorp \de\ | 488 | New | $0 M | Nov 5, 2026 |
| 6 | Tower Research Capital LLC (TRC) | 196 | New | $0 M | Nov 16, 2026 |
| 7 | Simplex Trading, LLC | 152 | New | $0 M | Nov 4, 2026 |
| 8 | SBI Securities Co., Ltd. | 100 | New | $0 M | Oct 22, 2026 |
| 9 | Morgan Stanley | 50 | New | $0 M | Nov 13, 2026 |
| 10 | Northwestern Mutual Wealth Management Co | 17 | New | $0 M | Nov 13, 2026 |
Mutual funds holding Immutep Ltd#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 733,497 | $0 M | 0.49% | <0.01% | −9.4% | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 406,561 | $0 M | 0.03% | <0.01% | −44% | Jul 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 18,722 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 246,179 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 122,328 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 8,886 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 4,950 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 3,713 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 32,224 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust | 5,604 | $0 M | <0.01% | <0.01% | −94% | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 11 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Markets and events: Immutep Ltd#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-09-25 23:50 UTC, code T3, resumed 13:00 UTC
- 2026-03-06 11:33 UTC, code T3, resumed 23:00 UTC
Fails to deliver
- : 5,546 shares at $3.38
- : 1,100 shares at $4.34
- : 55 shares at $4.65
- : 573 shares at $4.71
- : 1,120 shares at $4.88
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Immutep Ltd scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in growth (2 of 6), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth2 of 6
- ✓Revenue grew in the newest year30.2%Revenue up 30.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years10.9%10.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median10.9%10.9% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.03 vs -0.02Diluted EPS -0.03 in fiscal 2025 against -0.02 the year before (report's currency).
- ✗Net income higher than five years earlier-$40 M-$40 M in fiscal 2025 against -$9 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$40 MNet income -$40 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-36.2%-36.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities11.7×Current ratio 11.69 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year21.2%Diluted shares up 21.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Immutep Ltd's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Net margin | -594.8% | -68.9% | |
| Return on equity | -36.2% | -61.0% | |
| Revenue growth, 3 years a year | 10.9% | 12.9% | |
| Revenue growth | 30.2% | 15.8% | |
| Free cash flow margin | -601.2% | -61.5% |
1of 7on the Piotroski tests of financial strength
- Net loss of $40 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$40 million.
- The share count rose 21.2% in the year.
Immutep Ltd: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in AUD millions; per-share figures in AUD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 | FY 2016to Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 10+31.8%100% | 7.8+50.7%100% | 5.2−23.1%100% | 6.8+70.3%100% | 4.0−76.0%100% | 16+120%100% | 7.5+1.9%100% | 7.4+74.2%100% | 4.2+108%100% | 2.0—100% | |
| Research and development | 50+58.2%482% | 31+9.3%401% | 29+13.6%554% | 25+111%375% | 12−22.8%303% | 16r20+13.1%94.4% | 14r17+37.8%184% | 10.0+32.7%136% | 7.5+6.6%178% | 7.1—348% | |
| General and administrative | 3.6−16.0%34.4% | 4.2+13.9%54.0% | 3.7+11.7%71.4% | 3.3+17.7%49.2% | 2.8−1.5%71.1% | 2.9+3.2%17.4% | 2.8r2.7+10.0%37.1% | 2.5+17.5%34.3% | 2.1−26.5%50.9% | 2.9—144% | |
| Interest and finance income | 5.3+36.2%51.2% | 3.9+313%49.5% | 0.9+318%18.1% | 0.2+113%3.3% | 0.1−47.2%2.7% | 0.2−49.8%1.2% | 0.4+124%5.3% | 0.2+69.8%2.4% | 0.1−60.5%2.5% | 0.3—13.0% | |
| Interest expense and finance costs | 0.0+21.2%0.4% | 0.0+50.0%0.4% | 0.0−77.9%0.4% | 0.1+841%1.4% | 0.0−6.0%0.2% | 0.0—0.1% | 0—0.0% | — | — | 0.0—0.4% | |
| Income before tax | −61—−595% | −43—−545% | −40—−767% | −32—−477% | −30—−754% | −13—−81.6% | −18—−245% | −13—−173% | −10—−239% | −63—−3115% | |
| Income tax | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.0+3.0%0.0% | 0.0−10.8%0.0% | 0.0—0.0% | 0−100%0.0% | 0.0—0.0% | −0.7—−17.5% | −1.2—−58.2% | |
| Net income including minority interests | −61—−595% | −43—−545% | −40—−767% | −32—−477% | −30—−754% | −13—−81.6% | −18—−245% | −13—−173% | −9.4—−222% | −62—−3057% | |
| Net income attributable to shareholders | −61—−595% | −43—−545% | −40—−767% | −32—−477% | −30—−754% | −13—−81.6% | −18—−245% | −13—−173% | −9.4—−222% | −62—−3057% | |
| Earnings per share, basic | -0.04—— | -0.04—— | -0.04—— | -0.04—— | -0.05r-5.03—— | -0.03r-3.36—— | -5.29r-0.57—— | -4.63r-0.49—— | -0.40r-0.41—— | -2.78—— | |
| Earnings per share, diluted | -0.04—— | -0.04—— | -0.04—— | -0.04—— | -0.05r-5.03—— | -0.03r-3.36—— | -5.29r-0.57—— | -4.63r-0.49—— | -0.40r-0.41—— | -2.78—— | |
| Shares, weighted average (basic) | 1,456+21.2%— | 1,201+34.6%— | 892+5.1%— | 849+42.7%— | 595+44.1%— | 413r401+19.0%— | 347r3,226+26.1%— | 275r2,608−88.4%— | 2,370r2,284+6.4%— | 2,228—— | |
| Shares, weighted average (diluted) | 1,456+21.2%— | 1,201+34.6%— | 892+5.1%— | 849+42.7%— | 595+44.1%— | 413r401+19.0%— | 347r3,226+26.1%— | 275r2,608−88.4%— | 2,370r2,284+6.4%— | 2,228—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 67−58.3%42.9% | 162+31.1%80.3% | 123+54.3%83.7% | 80+32.0%78.3% | 61+130%73.9% | 26+58.9%56.5% | 17−29.4%40.9% | 23+91.8%49.9% | 12−41.4%35.0% | 21—49.1% | |
| Short-term investments | 62+210%39.7% | 20—10.0% | 0—0.0% | — | — | — | — | — | — | — | |
| Receivables | 9.9+34.3%6.3% | 7.4−7.6%3.6% | 8.0−5.0%5.4% | 8.4+36.7%8.2% | 6.1+85.9%7.5% | 3.3−36.6%7.1% | 5.2+51.3%12.8% | 3.4+56.4%7.3% | 2.2—6.3% | — | |
| Other current assets | 9.5+349%6.1% | 2.1−40.9%1.1% | 3.6+47.2%2.4% | 2.4+43.5%2.4% | 1.7+10.8%2.1% | 1.5−13.7%3.3% | 1.8+2.5%4.4% | 1.7+16.6%3.7% | 1.5—4.3% | — | |
| Current assets | 149−22.1%95.0% | 191+41.8%94.9% | 135+48.6%91.5% | 91+32.7%88.9% | 68+120%83.4% | 31+32.3%66.9% | 24−17.8%58.1% | 29+79.9%60.9% | 16—45.5% | — | |
| Property, plant and equipment | 0.1+0.5%0.0% | 0.1−24.1%0.0% | 0.1+119%0.1% | 0.0−7.2%0.0% | 0.0−17.2%0.0% | 0.0−6.8%0.1% | 0.1+100%0.1% | 0.0+9.3%0.1% | 0.0−23.2%0.1% | 0.0—0.1% | |
| Right-of-use (leased) assets | 0.5−17.9%0.3% | 0.6+60.0%0.3% | 0.4+42.7%0.3% | 0.3+0.5%0.3% | 0.3+33.6%0.3% | 0.2—0.4% | 0—0.0% | — | — | — | |
| Non-current assets | 7.9−22.9%5.0% | 10−18.1%5.1% | 12+9.9%8.5% | 11−16.6%11.1% | 14−11.9%16.6% | 15−9.1%33.1% | 17−7.4%41.9% | 18−3.6%39.1% | 19—54.5% | — | |
| Total assets | 157−22.1%100% | 202+36.7%100% | 147+44.3%100% | 102+24.6%100% | 82+76.0%100% | 47+14.9%100% | 41−13.7%100% | 47+34.4%100% | 35−17.8%100% | 43—100% | |
| Accounts payable | 11+11.2%6.8% | 9.6+6.0%4.7% | 9.0+56.9%6.1% | 5.8+20.3%5.6% | 4.8+63.0%5.8% | 2.9−42.0%6.3% | 5.1+38.1%12.5% | 3.7+41.5%7.8% | 2.6—7.4% | — | |
| Current liabilities | 13+21.7%8.1% | 10+7.3%5.2% | 9.8+52.3%6.6% | 6.4+20.1%6.3% | 5.3+58.7%6.5% | 3.4−36.5%7.2% | 5.3+37.5%13.1% | 3.9+46.4%8.2% | 2.6—7.5% | — | |
| Lease liabilities (non-current) | 0.3−21.2%0.2% | 0.4+92.4%0.2% | 0.2+93.1%0.1% | 0.1+34.2%0.1% | 0.1−39.8%0.1% | 0.1—0.3% | 0—0.0% | — | — | — | |
| Non-current liabilities | 0.6−62.5%0.4% | 1.6+30.1%0.8% | 1.2−28.0%0.8% | 1.7−50.9%1.6% | 3.4−65.6%4.2% | 9.9−8.5%21.3% | 11+12.8%26.8% | 9.6+65.9%20.5% | 5.8—16.6% | — | |
| Total liabilities | 13+10.7%8.5% | 12+9.8%6.0% | 11+35.7%7.4% | 8.1−7.6%7.9% | 8.8−34.1%10.7% | 13−17.7%28.5% | 16+19.9%39.8% | 13+59.8%28.7% | 8.4+16.5%24.1% | 7.2—17.0% | |
| Retained earnings | −444—−283% | −383—−190% | −340—−231% | −302—−296% | −275—−335% | −276—−592% | −262—−647% | −245—−520% | −232—−663% | — | |
| Shareholders' equity | 144−24.2%91.5% | 190+38.9%94.0% | 136+45.1%92.6% | 94+28.4%92.1% | 73+120%89.3% | 33+36.5%71.5% | 24−27.2%60.2% | 34+26.3%71.3% | 27—75.9% | — | |
| Total equity | 144−24.2%91.5% | 190+38.9%94.0% | 136+45.1%92.6% | 94+28.4%92.1% | 73+120%89.3% | 33+36.5%71.5% | 24−27.2%60.2% | 34+26.3%71.3% | 27−24.9%75.9% | 35—83.0% | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.4+5.6%23.1% | 2.3+9.7%28.9% | 2.1−0.1%39.6% | 2.1−0.3%30.5% | 2.1−0.5%52.2% | 2.1+10.7%12.6% | 1.9+3.9%25.1% | 1.8+6.3%24.6% | 1.7−14.6%40.3% | 2.0—98.2% | |
| Share-based compensation | 1.2−35.2%11.3% | 1.8−10.3%22.9% | 2.0+34.6%38.5% | 1.5−12.6%22.0% | 1.7−1.3%42.9% | 1.7+9.0%10.5% | 1.6−30.1%21.1% | 2.3+163%30.8% | 0.9−58.1%20.4% | 2.1—101% | |
| Cash from operating activities | −62—−601% | −35—−444% | −35—−680% | −30—−447% | −18—−445% | −11—−65.7% | −15—−204% | −7.8—−106% | −8.5—−202% | −11—−557% | |
| Capital expenditure | −0.0—−0.4% | −0.0—−0.4% | −0.1—−1.6% | −0.0—−0.3% | −0.0—−0.4% | −0.0—−0.1% | −0.0—−0.6% | −0.0—−0.2% | −0.0—−0.2% | −0.0—−1.3% | |
| Intangible assets bought | −0.2—−2.2% | −0.9—−11.5% | 0—0.0% | 0—0.0% | — | — | — | — | — | — | |
| Cash from investing activities | −39—−373% | −21—−268% | −0.1—−1.6% | −0.0—−0.3% | −0.0—−0.4% | −0.0—−0.1% | −0.0—−0.6% | −0.0—−0.2% | −0.0−106%−0.2% | 0.1—5.1% | |
| Debt repaid | — | — | — | — | — | — | — | — | — | −1.5—−74.3% | |
| Cash from financing activities | −0.5−101%−5.1% | 95+25.2%1214% | 76+51.1%1462% | 50−4.5%745% | 53+157%1328% | 20+156%124% | 8.0−56.5%107% | 18—250% | −0.0−100%−0.2% | 26—1268% | |
| Exchange-rate effect on cash | 6.7—65.1% | −1.0−134%−12.3% | 2.8—54.6% | −0.7—−9.9% | −0.8−659%−19.0% | 0.1−67.0%0.8% | 0.4−34.5%5.4% | 0.6—8.5% | −0.1—−2.9% | −0.4—−19.4% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Immutep Ltd compares in Biotechnology
- Market cap$56 M · higher than 28% of 726
- Revenue$7 M · higher than 38% of 647
- Net margin-594.8% · higher than 10% of 408
- Revenue growth30.2% · higher than 66% of 438
- Price / sales8.4× · lower than 48% of 339
- Price / book0.6× · lower than 89% of 534
- FCF yield-71.8% · higher than 15% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Immutep Ltd🇦🇺 | $56 M | — | -594.8% | +30.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending June-2025
- Balance sheet:
- As of June-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Immutep Ltd? Verify and update this profile — free
Show Immutep Ltd's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.